UA107845C2 - Benzimidazole derivatives as inhibitors pi3-kinase - Google Patents

Benzimidazole derivatives as inhibitors pi3-kinase

Info

Publication number
UA107845C2
UA107845C2 UAA201303058A UAA201303058A UA107845C2 UA 107845 C2 UA107845 C2 UA 107845C2 UA A201303058 A UAA201303058 A UA A201303058A UA A201303058 A UAA201303058 A UA A201303058A UA 107845 C2 UA107845 C2 UA 107845C2
Authority
UA
Ukraine
Prior art keywords
relates
present
benzimidazole derivatives
kinases
treatment
Prior art date
Application number
UAA201303058A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Junya Qu
Ralph Rivero
Robert Sanchez
Rosanna Tedesco
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Priority claimed from PCT/US2011/052857 external-priority patent/WO2012047538A1/en
Publication of UA107845C2 publication Critical patent/UA107845C2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Даний винахід стосується застосування похідних бензімідазолу для модуляції, а саме інгібування активності або функції родини фосфоїнозитид 3' ОН кіназ (в подальшому РІ3-кіназ), відповідно, РІ3Кα, РІ3Кδ, РІ3Кβ та/або РІЗКγ. Відповідно, представлений винахід стосується застосування бензімідазолів в лікуванні одного або більше хворобливих станів, вибраних з: аутоімунних розладів, запальних захворювань, серцево-судинних захворювань, нейродегенеративних захворювань, алергії, астми, панкреатиту, поліорганної недостатності, захворювань нирок, агрегації тромбоцитів, раку, рухливості сперматозоїдів, відторгнення при трансплантації, відторгнення трансплантату або ушкодження легень. Більш відповідно, представлений винахід стосується РІ3Кβ селективних бензімідазольних сполук для лікування раку.The present invention relates to the use of benzimidazole derivatives for modulation, namely the inhibition of the activity or function of a family of phosphoinositide 3 'OH kinases (hereinafter PI3-kinases), respectively, PI3Kα, PI3Kδ, PI3Kβ and / or RISKγ. Accordingly, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergies, asthma, pancreatitis, multiple organ dysfunction, motion sickness, disease sperm, transplant rejection, transplant rejection, or lung damage. More appropriately, the present invention relates to PI3Kβ selective benzimidazole compounds for the treatment of cancer.

UAA201303058A 2010-10-06 2011-09-23 Benzimidazole derivatives as inhibitors pi3-kinase UA107845C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39031410P 2010-10-06 2010-10-06
PCT/US2011/052857 WO2012047538A1 (en) 2010-10-06 2011-09-23 Benzimidazole derivatives as pi3 kinase inhibitors

Publications (1)

Publication Number Publication Date
UA107845C2 true UA107845C2 (en) 2015-02-25

Family

ID=52989832

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201303058A UA107845C2 (en) 2010-10-06 2011-09-23 Benzimidazole derivatives as inhibitors pi3-kinase

Country Status (1)

Country Link
UA (1) UA107845C2 (en)

Similar Documents

Publication Publication Date Title
EA201390302A1 (en) DERIVATIVES OF BENZIMIDAZOLE AS PI3 KINAZ INHIBITORS
PH12017501766A1 (en) Heterocyclylamines as pi3k inhibitors
EA201390579A1 (en) HINAZOLIN-4 (3H) -ONE DERIVATIVES USED AS PI3-KINASE INHIBITORS
GT201200315A (en) APOPTOSIS INDUCTIVE AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
MY162507A (en) Pyrimidinones as pi3k inhibitors
UA108743C2 (en) HINAZOLINE-4 (3H) -ONE DERIVATIVES FOR APPLICATION AS RI-KINASE INHIBITORS
BR112015028501A2 (en) bipirazole derivatives as jak inhibitors
CL2012001073A1 (en) Compounds derived from pyrido [4,3-d] pyrimidin-5-one, their pharmaceutical compositions and their use as kinase inhibitors to treat asthma, COPD, ulcerative colitis, bronchitis, lupus, breast cancer, Alzheimer's disease, Alzheimer's disease parkinson's, osteoporosis, multiple sclerosis, diabetes, eye disorders, restenosis, inflammatory diseases.
MD20150085A2 (en) Inhibitors of histone demethylases
BR112013023876A2 (en) pyrroltriazinone derivatives as pi3k inhibitors
MX2022010638A (en) Pde9 inhibitors for treatment of peripheral diseases.
UA113186C2 (en) Macrocyclic LRRK2 Kinase Inhibitors
PH12015501836A1 (en) 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
UA107845C2 (en) Benzimidazole derivatives as inhibitors pi3-kinase
MX2017003016A (en) Pyridazinone derivatives as phosphoinositide 3-kinases inhibitors.
EA201171030A1 (en) 2-MORFOLINOPIRIDO [3,2-d] Pyrimidines
ECSP12011628A (en) PYRIMIDINONES AS PI3K INHIBITORS
UA111088C2 (en) Pyridinylpyrazoloquinoline compound
DK201170064A (en) Halophenyl isothiocyanates for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns